Hemofil M Related Published Studies
Well-designed clinical trials related to Hemofil M (Antihemophilic Factor)
Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group. [2000.06]
Pharmacokinetic in vivo comparison using 1-stage and chromogenic substrate assays with two formulations of Hemofil-M. [1996.12]
Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M). The Recombinate Study Group. [1992.10.05]
Well-designed clinical trials possibly related to Hemofil M (Antihemophilic Factor)
Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A. [2008.09]
Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor. [2008.06]
Effect of oral melatonin on the procoagulant response to acute psychosocial stress in healthy men: a randomized placebo-controlled study. [2008.05]
Percutaneous liver biopsy in hemophiliac children with chronic hepatitis C virus infection. [2008.04]
p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. [2008.04]
Oral melatonin reduces blood coagulation activity: a placebo-controlled study in healthy young men. [2008.03]
Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. [2008.02]
A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass. [2008.02]
Understanding tubulin/microtubule-taxane interactions: a quantitative structure-activity relationship study. [2008.01]
Prevention of haemophilic synovitis: prophylaxis. [2007.11]
Analysing two dinucleotide repeats of FVIII gene in Iranian population. [2007.11]
Dosing factor VIIa (recombinant) in nonhemophiliac patients with bleeding after cardiac surgery. [2007.09.01]
A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation. [2007.09]
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. [2007.08.09]
Volume Replacement Therapy during Major Orthopedic Surgery Using Voluven(R) (Hydroxyethyl Starch 130/0.4) or Hetastarch. [2007.06]
Effect of depomedroxyprogesterone acetate on coagulation parameter: a pilot study. [2007.06]
Exhaustive exercise with high eccentric components induces prothrombotic and hypofibrinolytic responses in boys. [2007.03]
A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura. [2007.02]
A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A. [2007.02]
Evaluation of pharmacokinetics, efficacy and safety of Immunate solvent detergent in previously treated patients with severe haemophilia A. [2007.01]
Assessing Efficacy and Therapeutic Claims in Emerging Indications for Recombinant Factor VIIa: Regulatory Perspectives. [2006.01]
Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. [2006]
Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. [2005.10]
Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. [2005.04]
B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study. [2005.03]
Effectiveness in controlling haemorrhage after dental scaling in people with haemophilia by using tranexamic acid mouthwash. [2005.01.08]
Comparing hand-held computers and paper diaries for haemophilia home therapy: a randomized trial. [2004.11]
Thawed cryoprecipitate stored for 6 h at room temperature: a potential alternative to factor VIII concentrate for continuous infusion. [2004.11]
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. [2004.09]
Impact of highly purified urinary FSH and recombinant FSH on haemostasis: an open-label, randomized, controlled trial. [2004.04]
Fresh frozen plasma in the pediatric pump prime: a prospective, randomized trial. [2004.03]
Effects of oxypolygelatin and dextran 70 on hemostatic variables in dogs. [2003.10]
The effects of intermittent prebypass heparin dosing in patients undergoing coronary artery bypass grafting. [2003.09]
Cryoprecipitate for the correction of coagulopathy associated with liver disease. [2003.08]
Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus. [2003.08]
Prospective controlled studies on prophylaxis: an Italian approach. [2003.05]
Repetitive large-dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury. [2003.05]
Comparison of RBCs and FFP with whole blood during liver transplant surgery. [2003.03]
The influence of crystalloid and colloid replacement solutions in acute normovolemic hemodilution: a preliminary survey of hemostatic markers. [2003.02]
The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. [2003.01]
Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women. [2002.12]
The effects of perioperatively administered colloids and crystalloids on primary platelet-mediated hemostasis and clot formation. [2002.10]
Tumor angiogenesis as a predictive marker for organ preservation in patients with advanced laryngeal carcinoma. [2002.05]
Desmopressin usage in elective cardiac surgery. [2001.12]
Effects of hormone replacement on hemostasis in spontaneous menopause. [2001.06]
Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80 degrees C terminal dry heat treatment in patients with haemophilia A. [2000.05]
Safety and immunogenicity of subcutaneous hepatitis A vaccine in children with haemophilia. [2000.03]
Pharmacokinetics of recombinant factor VIII (recombinate) using one-stage clotting and chromogenic factor VIII assay. [1999.12]
Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. [1999.08.17]
Pharmacokinetics and acute tolerance of a double virus inactivated plasma derived factor VIII concentrate. [1999.07]
Acquired APC resistance in neurosurgical patients may not be a risk factor for postoperative deep vein thrombosis. [1999.04]
Procoagulant activity and cytokine expression in whole blood cultures from patients with atherosclerosis supplemented with omega-3 fatty acids. [1999.04]
Comparison of the effects of two low fat diets with different alpha-linolenic:linoleic acid ratios on coagulation and fibrinolysis. [1999.01]
Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. [1998.11]
Application of cryoprecipitate as a hematostatic glue. [1998.10]
Type 2N von Willebrand disease: rapid genetic diagnosis of G2811A (R854Q), C2696T (R816W), T2701A (H817Q) and G2823T (C858F)--detection of a novel candidate type 2N mutation: C2810T (R854W). [1998.07]
Conjugated estrogen reduces transfusion and coagulation factor requirements in orthotopic liver transplantation. [1998.06]
Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease. [1998]
Partial blockade of nitric oxide synthase blunts the exercise-induced increase of von Willebrand factor antigen and of factor VIII in man. [1997.10]
Superior in vivo response of recombinant factor VIII concentrate in children with hemophilia A. [1997.04]
Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. [1997.02]
The effects of desmopressin and 6% hydroxyethyl starch on factor VIII:C. [1996.10]
Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. [1996.09]
Formation of antibodies to factor VIII in patients with hemophilia A who are treated with interferon for chronic hepatitis C. [1996.08.15]
Effects of supplemental dietary arginine, canola oil, and trace elements on cellular immune function in critically injured patients. [1996.07]
A pharmacokinetic study of an ion-exchange solvent-detergent-treated high-purity factor VIII concentrate. Haemophilia Directors for Scotland and Northern Ireland. [1995.12]
Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. A double-blind placebo-controlled trial. [1995.10]
Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. [1995.10]
Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass. A double-blind placebo-controlled study. [1995.10]
The effect of aspirin on haemostatic activity in the treatment of chronic venous leg ulceration. [1995.03]
Bovine factor VIII derivative in the treatment of non-proliferative diabetic retinopathy. [1995]
Study of the interaction of dextran and enoxaparin on haemostasis in humans. [1994.11]
A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting. [1994.02]
A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. [1993.11.15]
Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status. [1993.09.18]
Estrogen and progesterone receptors in human decidua after RU486 treatment. [1993.07]
Fibrinolytic and hemostatic parameter response after resistance exercise. [1993.05]
A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. [1993.02.01]
Anaesthesia affects plasma concentrations of vasopressin, von Willebrand factor and coagulation factor VIII in cardiac surgical patients. [1993.02]
The effect of epidural blockade on postoperative hypercoagulability following abdominal aortic bypass surgery. [1992.11]
A trial of desmopressin to reduce blood loss in patients undergoing spinal fusion for idiopathic scoliosis. [1992.09]
Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. [1992.06.15]
Pharmacokinetics of two pasteurized factor VIII concentrates by different and multicenter assays of factor VIII activity. [1992.03.15]
Immune status of asymptomatic HIV-infected hemophiliacs: randomized, prospective, two-year comparison of treatment with a high-purity or an intermediate-purity factor VIII concentrate. [1992.03.02]
Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography. [1992.01.23]
Haemostatic responses to desmopressin acetate after primary coronary artery bypass surgery. [1992]
A randomized placebo-controlled double-blind study of danazol in hemophilia A. [1992]
In vivo recovery and survival of monoclonal-antibody-purified factor VIII concentrates. [1991.12.02]
Effects on coagulation and fibrinolysis of desmopressin in patients undergoing total hip replacement. [1991.12.02]
Cytotoxic suppression of acquired factor VIII:C inhibitors. [1991.11.04]
The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: a randomized, prospective, two-year comparison with an intermediate purity concentrate. [1991.10.15]
Observation of the activity of factor VIII in the endometrium of women pre- and post-insertion of three types of IUDs. [1991.10]
Changes in factor VIII: coagulant activity and von Willebrand factor antigen concentration after subcutaneous injection of desmopressin in dogs with mild hemophilia A. [1991.05]
Blood loss and safety with desmopressin or placebo during aorto-iliac graft surgery. [1991.04]
Hemostatic changes in women using a monthly injectable contraceptive for one year. [1990.10]
Levels of thrombin--antithrombin-III complex and factor VIII activity in relation to post-operative deep vein thrombosis and influence of prophylaxis with a low-molecular-weight heparin. [1990.10]
Coffee, caffeine and hemostasis: results from two randomized studies. [1990.08]
Lack of immune response to mouse IgG in hemophilia A patients treated chronically with Monoclate, a monoclonal antibody affinity purified factor VIII preparation. [1990.06.28]
|
